Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinoma (RCC) with advanced disease, but biomarkers are lacking to predict which patients will benefit. This study proposes potential immunological biomarkers that could developed for predicting therapeutic...
Main Authors: | Yuan Liu, Haydn Kissick, Viraj A Master, Mehmet A Bilen, Omer Kucuk, Bradley C Carthon, Nataliya Prokhnevska, Ewelina Sobierajska, Rachel Greenwald, Adeboye Osunkoya, Jennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, Adriana Moon Reyes, Luke Del Balzo, Patrick Connor Mullane, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G Sowalsky |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/7/e004803.full |
Similar Items
-
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
by: Viraj A. Master, et al.
Published: (2023-01-01) -
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
by: Caroline S. Jansen, et al.
Published: (2023-10-01) -
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
by: Tony Zibo Zhuang, et al.
Published: (2022-12-01) -
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
by: Haydn Kissick, et al.
Published: (2024-03-01) -
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
by: Julie M. Shabto, et al.
Published: (2020-04-01)